Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

MLA

Rens Braster, et al. “Human IgG3 with Extended Half-Life Does Not Improve Fc-Gamma Receptor-Mediated Cancer Antibody Therapies in Mice.” PLoS ONE, vol. 12, no. 5, Jan. 2017, p. e0177736. EBSCOhost, https://doi.org/10.1371/journal.pone.0177736.

APA

Rens Braster, Simran Grewal, Remco Visser, Helga K Einarsdottir, Marjolein van Egmond, Gestur Vidarsson, & Marijn Bögels. (2017). Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice. PLoS ONE, 12(5), e0177736. https://doi.org/10.1371/journal.pone.0177736

Chicago

Rens Braster, Simran Grewal, Remco Visser, Helga K Einarsdottir, Marjolein van Egmond, Gestur Vidarsson, and Marijn Bögels. 2017. “Human IgG3 with Extended Half-Life Does Not Improve Fc-Gamma Receptor-Mediated Cancer Antibody Therapies in Mice.” PLoS ONE 12 (5): e0177736. doi:10.1371/journal.pone.0177736.